Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease

Venkataraman, P.; Kawakami, Hiroshi; Huynh, Quan; Mitchell, Geoffrey; Nicholls, Stephen J.; Stanton, Tony; Tonkin, Andrew; Watts, Gerald F.; Marwick, Thomas H.; Investigators, Caught-Cad

doi:10.1016/j.jcmg.2020.11.008

Cited by 22 publications

(15 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a microsimulation model of 1083 individuals with a family history of premature CAD, compared with traditional risk factor–based prediction alone, use of CAC scanning was more costly ($145) and more effective (0.0097 QALY) with an incremental cost-effective ratio of $15 014/QALY. 72 The incremental cost-effective ratio improved in the male, >60 years of age, and ≥7.5% 10-year risk subgroups, whereas CAC was not cost-effective in individuals with <5% 10-year risk or those 40 to 50 years of age.…”

Section: Subclinical Atherosclerosismentioning

confidence: 90%

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Tsao¹,

Aday²,

Almarzooq³

et al. 2023

Circulation

3,184

702

View full text Add to dashboard Cite

BACKGROUND: The American Heart Association, in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, diet, and weight) and health factors (cholesterol, blood pressure, and glucose control) that contribute to cardiovascular health. The Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, congenital heart disease, rhythm disorders, subclinical atherosclerosis, coronary heart disease, heart failure, valvular disease, venous disease, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs). METHODS: The American Heart Association, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2023 Statistical Update is the product of a full year’s worth of effort in 2022 by dedicated volunteer clinicians and scientists, committed government professionals, and American Heart Association staff members. The American Heart Association strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives. This year’s edition includes additional COVID-19 (coronavirus disease 2019) publications, as well as data on the monitoring and benefits of cardiovascular health in the population, with an enhanced focus on health equity across several key domains. RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics. CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.

show abstract

Section: Subclinical Atherosclerosismentioning

confidence: 90%

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Tsao¹,

Aday²,

Almarzooq³

et al. 2023

Circulation

3,184

702

View full text Add to dashboard Cite

show abstract

“…In a microsimulation model of 1083 individuals with a family history of premature CAD, compared with traditional risk factor–based prediction alone, use of CAC scanning was more costly ($145) and more effective (0.0097 QALY) with an incremental cost-effective ratio of $15 014/QALY. 94 The incremental cost-effective ratio improved in the male, >60 years of age, and ≥7.5% 10-year risk subgroups, whereas CAC was not cost-effective in individuals with <5% 10-year risk or those 40 to 50 years of age.…”

Section: Subclinical Atherosclerosismentioning

confidence: 90%

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Martin,

Aday,

Almarzooq

et al. 2024

Circulation

216

View full text Add to dashboard Cite

BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs). METHODS: The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2024 AHA Statistical Update is the product of a full year’s worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members. The AHA strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives. This year’s edition includes additional global data, as well as data on the monitoring and benefits of cardiovascular health in the population, with an enhanced focus on health equity across several key domains. RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics. CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.

show abstract

“…A microsimulation model by Venkataraman et al [211] including asymptomatic 1083 participants of CAUGHT-CAD trial (Coronary Artery calcium score use to guide management of Hereditary CAD) with FHCAD (Family history of premature coronary artery disease) at intermediate risk for evaluating cost-effectiveness of CAC-guided strategy in statin initiation in terms of improvement in QALY with direct medical costs (CAC testing, examinations of incidental findings, increased life-time risk of radiation-induced cancer) through incrementally comparing with standard care model indication by PCE 10-year risk (≥7.5%) on ICER index at which all model costs were in 2020 USD consumer price besides including 1-time utility decrement of statin disutility and statin related complications into base-case model, reported in base-case analysis CAC strategy (CACs > 0) vs PCE ≥ 7.5% had significantly higher cost-effectiveness of ICER ($15014), average cost ($6059 vs $5914, Δ:$145) and person-years of statin therapy (794482vs342592) yet lower than treat-all strategy, greater number of major statin complications (5405vs1945), lesser aversion of person-years with symptomatic CVD, prevented 1314 more CVD-events and 476 deaths, and had NNS (to prevent 1 CVD event) of 152, moreover, according to sensitivity analysis at WTP=$50000 CAC strategy was cost-effective for baseline PCE 5.0–7.5% and cost-saving for baseline PCE ≥ 7.5% but not cost-effective for low risk PCE < 5%, furthermore, addition of aspirin to statin treatment for those with CACs ≥ 100 increased cost $63 (to $6005) and QALY 0.0069 (to 9.3932) but prevented 462 deaths and improved ICER to $8998/QALY and $27271/Life saved, moreover, if statin initiation in CAC strategies were increased to CACs ≥ 100 and 10 year MESA risk ≥ 5% ICER improved to $7000/QALY.…”

Section: Cost Effectiveness Of Cac Imagingmentioning

confidence: 99%

Subclinical cardiovascular disease and utility of coronary artery calcium score

Saydam¹

2021

IJC Heart & Vasculature

View full text Add to dashboard Cite

Cost-Effectiveness of Coronary Artery Calcium Scoring in People With a Family History of Coronary Disease

Cited by 22 publications

References 35 publications

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Subclinical cardiovascular disease and utility of coronary artery calcium score

Contact Info

Product

Resources

About